VYNE - VYNE Therapeutics GAAP EPS of -$0.16 revenue of $0.2M November, 10 2022 05:10 PM VYNE Therapeutics Inc Com VYNE Therapeutics press release ( NASDAQ: VYNE ): Q3 GAAP EPS of -$0.16. Revenue of $0.2M (+53.8% Y/Y). As of September 30, 2022, VYNE had cash and cash equivalents and restricted cash of $35.6 million. For further details see: VYNE Therapeutics GAAP EPS of -$0.16, revenue of $0.2M